Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07144150 · ClinicalTrials.gov registry record · NA
EVERO Drug-coated Balloon (DCB) Randomized Trial
A NA study, sponsored by Cook Research Incorporated.
- Recruiting
- Registry status
- NA
- Development phase
- 410
- Enrollment target
NCT07144150 is a NA study that is actively recruiting participants, run by Cook Research Incorporated. The registered enrollment target is 410 participants.
The verdict
NCT07144150, a NA study, is actively recruiting participants, sponsored by Cook Research Incorporated.
- RECRUITING
- Registry status
- NA
- Development phase
- 410 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \[DCB\]) in the treatment of the femoropopliteal artery lesions in patients with peripheral arterial disease (PAD). Specifically, the Randomized-Controlled Trial (RCT) is designed to demonstrate non-inferior safety and non-inferior effectiveness of the Evero DCB when compared to commercially available paclitaxel DCBs (pDCBs).
Interventions
- COMBINATION_PRODUCT Evero DCB
- COMBINATION_PRODUCT Paclitaxel DCB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2026-04-17 |
| Est. Completion | 2032-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07144150
The ClinicalTrials.gov registry entry for NCT07144150 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 410 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cook Research Incorporated, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Evero DCB is the first listed.
NCT07144150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07144150 about?
NCT07144150 is a clinical study titled "EVERO Drug-coated Balloon (DCB) Randomized Trial". The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \[DCB\]) in the treatment of the femoropopliteal artery l...
What is the current status of trial NCT07144150?
This trial is currently recruiting. It is a NA study. The enrollment target is 410 participants. The study started on 2026-04-17. Estimated completion is 2032-10.
What interventions are being tested in trial NCT07144150?
The interventions under investigation include: Evero DCB (COMBINATION_PRODUCT), Paclitaxel DCB (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07144150?
This trial is sponsored by Cook Research Incorporated, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.